Provided by Tiger Fintech (Singapore) Pte. Ltd.

AC Immune SA

1.70
+0.0000
Pre-market: 1.790.0900+5.29%07:03 EDT
Volume:104.85K
Turnover:178.86K
Market Cap:168.20M
PE:-3.02
High:1.77
Open:1.73
Low:1.66
Close:1.70
Loading ...

BRIEF-AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Reuters
·
2 hours ago

AC Immune: Q1 Earnings Snapshot

Associated Press Finance
·
2 hours ago

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
2 hours ago

AC Immune Sa: Cash Resources of CHF 145.7 Mln as of March 31 Provides Funding Into Q1 2027

THOMSON REUTERS
·
2 hours ago

AC Immune Q1 EPS CHF -0.19

THOMSON REUTERS
·
2 hours ago

AC Immune Q1 Operating Expenses CHF -20.36 Million

THOMSON REUTERS
·
2 hours ago

AC Immune Q1 Pretax Profit CHF -19.029 Million

THOMSON REUTERS
·
2 hours ago

AC Immune Q1 Operating Income CHF -19.37 Million

THOMSON REUTERS
·
2 hours ago

Individual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last week

Simply Wall St.
·
26 Apr

AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

BRIEF-AC Immune SA - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date

Reuters
·
02 Apr

AC Immune Sa - ACI-7104.056 Is Well Tolerated With No Safety Issues Reported to Date

THOMSON REUTERS
·
02 Apr

AC Immune Reports Further Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

THOMSON REUTERS
·
02 Apr

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

GlobeNewswire
·
02 Apr

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

GlobeNewswire
·
25 Mar

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

Zacks
·
25 Mar

AC Immune Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

AC Immune SA reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Mar

AC Immune SA Reports 2024 Financial Results and Strategic Advances

TIPRANKS
·
13 Mar

AC Immune FY24 EPS CHF(0.51) vs CHF(0.64) YoY; Contract Revenues CHF27.3M

Benzinga
·
13 Mar